Menu
Recruiting NCT06810011

Eye Diseases "Treated" With Interoperable Medical Informatics

Observational Intravitreal Injections

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Intravitreal Injections. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Germany
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

EyeMatics - Eye Diseases "Treated" With Interoperable Medical Informatics

Overview

The overarching goal of EyeMatics is to promote an interoperable, sustainable infrastructure for the integration and sharing of data from clinical research to improve personalized medicine in ophthalmology. To achieve this, EyeMatics bundles the expertise and preliminary work of the four consortia of the Medical Informatics Initiative (MII) and the ophthalmological centers of excellence in Germany. The perspective and concerns of patients will be strongly incorporated into the project work through close cooperation with patient representatives and the inclusion of patient feedback on quality of life and treatment success. EyeMatics aims to improve the understanding of the therapeutic success of eye diseases that are usually treated with intravitreal surgical medication (IVOM). To this end, an exemplary analysis platform for "real" clinical data will be provided and a dashboard for data visualization and analysis will be developed as a web application. The dashboard is to be introduced at all participating hospital sites for research purposes.

Primary outcome measures

  • Medical success [Time frame: with every treatment or controll-visit within 12, 24 and 36 months]
Secondary outcome measures (5)
  • Treatment latency period: [Time frame: from indication to treatment begin (Depending on the treatment regimen, assessed up to 6 months)]
  • Treatment and monitoring frequency [Time frame: during the procedure]
  • Treatment adherence [Time frame: during the procedure]
  • Treatment persistence [Time frame: during the procedure]
  • Patient-relevant outcomes (PROMs) [Time frame: every 6 months within 12, 24 and 36 months]

Eligibility criteria

Inclusion criteria

  • OPS code: "5-156.9 Injection of drugs into the posterior segment of the eye"

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

Germany · 6 centers
  • Klinikum Chemnitz gGmbH — Chemnitz
  • Universitätsklinikum Aachen, AöR — Aachen
  • Universitätsmedizin Greifswald — Greifswald
  • Universität Leipzig — Leipzig
  • Universität Münster — Münster
  • Universitätsklinikum Tübingen — Tübingen

Publications

  • Holtrup L, Varghese J, Schuster AK, Poschkamp B, Hampf C, Waltemath D, Wahle L, Lipprandt M, Merle DA, Berens P, Kohlbacher O, Kakkassery V, Bartos M, Ziemssen F, Wendt T, Hoffmann K; EyeMatics Study Group; Eter N. [EyeMatics-Multicenter data evaluation of real-world data with interoperable medical informatics]. Ophthalmologie. 2025 Apr;122(4):270-277. doi: 10.1007/s00347-024-02135-0. Epub 2024 No PMID 39542916

Identifiers

NCT: NCT06810011 · 01ZZ2319A-I · 01ZZ2319A-I

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗